- Home
- GHRS vs GBLI Comparison
GHRS vs GBLI Comparison
Compare GHRS & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- GBLI
- Stock Information
- Founded
- GHRS 2018
- GBLI 2016
- Country
- GHRS Ireland
- GBLI United States
- Employees
- GHRS N/A
- GBLI N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- GHRS Health Care
- GBLI Finance
- Exchange
- GHRS Nasdaq
- GBLI Nasdaq
- Market Cap
- GHRS 583.1M
- GBLI 476.1M
- IPO Year
- GHRS 2021
- GBLI 2003
- Fundamental
- Price
- GHRS $10.60
- GBLI $28.49
- Analyst Decision
- GHRS Strong Buy
- GBLI
- Analyst Count
- GHRS 8
- GBLI 0
- Target Price
- GHRS $30.63
- GBLI N/A
- AVG Volume (30 Days)
- GHRS 146.4K
- GBLI 3.3K
- Earning Date
- GHRS 05-08-2025
- GBLI 05-07-2025
- Dividend Yield
- GHRS N/A
- GBLI 4.85%
- EPS Growth
- GHRS N/A
- GBLI N/A
- EPS
- GHRS N/A
- GBLI 1.99
- Revenue
- GHRS N/A
- GBLI $437,447,000.00
- Revenue This Year
- GHRS N/A
- GBLI $8.70
- Revenue Next Year
- GHRS N/A
- GBLI $14.56
- P/E Ratio
- GHRS N/A
- GBLI $13.63
- Revenue Growth
- GHRS N/A
- GBLI N/A
- 52 Week Low
- GHRS $6.00
- GBLI $26.94
- 52 Week High
- GHRS $20.50
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- GHRS 59.36
- GBLI 39.61
- Support Level
- GHRS $9.81
- GBLI $26.94
- Resistance Level
- GHRS $11.50
- GBLI $29.63
- Average True Range (ATR)
- GHRS 0.72
- GBLI 0.87
- MACD
- GHRS 0.23
- GBLI 0.10
- Stochastic Oscillator
- GHRS 89.60
- GBLI 52.36
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.